Given the critical role that LSD1 plays in the function of malignant blood cells, targeting LSD1 offers a new mechanism for the treatment of blood cancers associated with high morbidity and mortality. The significant unmet need of patients and their families dealing with these high-risk disorders is what has driven us to develop internally discovered, novel inhibitors and degraders of LSD1. By advancing candidate drug products that inhibit LSD1, we hope to improve and prolong the lives of patients with cancer and bone marrow diseases.
We are using this scientific foundation to advance our internally discovered lead product candidate, bomedemstat, for the treatment of myeloproliferative neoplasms (MPNs): a family of related, chronic cancers of the bone marrow. Bomedemstat is an orally available, small molecule, inhibitor of LSD1. Currently, bomedemstat is being tested in clinical studies as a potentially disease-modifying monotherapy for essential thrombocythemia (ET), myelofibrosis (MF), polycythemia vera (PV) and potentially other indications.